Vignati G, Mauri L
Dipartimento Cardiologico De Gasperis, Ospedale Ca' Granda-Niguarda, Milano.
G Ital Cardiol. 1988 Feb;18(2):109-14.
We have evaluated 37 children with reentrant supraventricular tachycardia and followed them up for 3.9 +/- 2.7 years. Our 37 patients ranged in age from 1 day to 15 years (mean 4.6 +/- 4 years). When supraventricular tachycardia (SVT) began, 14 patients were less than 1 year old (Group A), and 23 were more than 1 year old (Group B). Cardiac heart disease occurred in 6 children, and Wolff-Parkinson-White syndrome was present in 7 children. After the initial episodes of SVT had been converted, chronic therapy was begun in 87% of cases (A 100%, B 78%) and continued for at least 12 months. During follow-up, therapy was discontinued with good results in 51% of patients (A 79%, B 39%). Recurrences were observed in 19% of cases (A 14%, B 22%), and WPW syndrome was a predisposing factor. Among those patients who were treated, none of the drug regimens used, proved significantly better in preventing recurrence.
the long-term prognosis of SVT is better in Group A than in B. In Group A it is possible to discontinue therapy in most cases; on the contrary in Group B chronic treatment is often necessary. In this group it is important to evaluate if and how the side effects of the drugs can change the long-term prognosis of these patients.
我们评估了37例折返性室上性心动过速患儿,并对他们进行了3.9±2.7年的随访。我们的37例患者年龄从1天至15岁不等(平均4.6±4岁)。室上性心动过速(SVT)发作时,14例患者年龄小于1岁(A组),23例患者年龄大于1岁(B组)。6例患儿患有心脏病,7例患儿存在预激综合征。在首次SVT发作得到转复后,87%的病例开始了长期治疗(A组100%,B组78%),并持续至少12个月。在随访期间,51%的患者停药后效果良好(A组79%,B组39%)。19%的病例出现复发(A组14%,B组22%),预激综合征是一个诱发因素。在接受治疗的患者中,所使用的任何药物治疗方案在预防复发方面均未显示出显著更好的效果。
A组SVT的长期预后优于B组。在A组,大多数情况下可以停药;相反,在B组通常需要长期治疗。在该组中,评估药物副作用是否以及如何改变这些患者的长期预后非常重要。